{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:22:26Z","timestamp":1791400946121,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40257-024-00855-2","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:01:43Z","timestamp":1714662103000},"page":"669-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Kuligowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May E.","family":"Venturanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"10247","key":"855_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"4","key":"855_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"855_CR3","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. Institute for Health Metrics and Evaluation, Seattle. 2020. https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"issue":"2","key":"855_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2310\/6620.2007.06034","volume":"18","author":"JM Hanifin","year":"2007","unstructured":"Hanifin JM, Reed ML, Eczema P, Impact WG. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82\u201391.\u00a0https:\/\/www.liebertpub.com\/doi\/full\/10.2310\/6620.2007.06034.","journal-title":"Dermatitis"},{"key":"855_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014what is new? Front Med (Lausanne). 2021;8: 644760. https:\/\/doi.org\/10.3389\/fmed.2021.644760.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"855_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2021.02.069","volume":"85","author":"BT Cheng","year":"2021","unstructured":"Cheng BT, Silverberg JI. Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study. J Am Acad Dermatol. 2021;85(4):885\u201392. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.069.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"855_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2021.0008","volume":"157","author":"J Wan","year":"2021","unstructured":"Wan J, Mitra N, Hooper SR, Hoffstad OJ, Margolis DJ. Association of atopic dermatitis severity with learning disability in children. JAMA Dermatol. 2021;157(6):1\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0008.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"855_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.023.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"855_CR9","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344. https:\/\/doi.org\/10.1111\/jdv.16892.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"855_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"855_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s13555-021-00580-2","volume":"11","author":"P Anderson","year":"2021","unstructured":"Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(5):1571\u201385. https:\/\/doi.org\/10.1007\/s13555-021-00580-2.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"855_CR12","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. Jak-Stat. 2013;2(3): e24137. https:\/\/doi.org\/10.4161\/jkst.24137.","journal-title":"Jak-Stat."},{"issue":"1","key":"855_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"15","key":"855_CR14","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317. https:\/\/doi.org\/10.1182\/blood-2009-04-214957.","journal-title":"Blood"},{"key":"855_CR15","unstructured":"Opzelura\u2122 (ruxolitinib cream). Full prescribing information. Wilmington: Incyte Corporation; 2023."},{"key":"855_CR16","unstructured":"Opzelura\u2122 (ruxolitinib cream). Summary of product characteristics. Amsterdam: Incyte Biosciences Distribution B.V.; 2023."},{"key":"855_CR17","unstructured":"Opzelura\u2122. ruxolitinib cream. Leatherhead: Incyte Biosciences UK Ltd; 2023."},{"issue":"4","key":"855_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield L, Leung DY, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"855_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"855_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abb\u00e9 A, Nelson L, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139. https:\/\/doi.org\/10.1111\/bjd.17744.","journal-title":"Br J Dermatol"},{"issue":"5","key":"855_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjd.18978","volume":"183","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Lai JS, Patel KR, Singam V, Vakharia PP, Chopra R, et al. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS\u00ae) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis. Br J Dermatol. 2020;183(5):891\u20138. https:\/\/doi.org\/10.1111\/bjd.18978.","journal-title":"Br J Dermatol"},{"issue":"7","key":"855_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2340\/00015555-2433","volume":"96","author":"A Reich","year":"2016","unstructured":"Reich A, Riepe C, Anastasiadou Z, Medrek K, Augustin M, Szepietowski JC, Stander S. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978\u201380. https:\/\/doi.org\/10.2340\/00015555-2433.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"855_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139. https:\/\/doi.org\/10.1001\/archderm.140.12.1513.","journal-title":"Arch Dermatol"},{"issue":"6","key":"855_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsy054","volume":"41","author":"CB Forrest","year":"2018","unstructured":"Forrest CB, Meltzer LJ, Marcus CL, de la Motte A, Kratchman A, Buysse DJ, et al. Development and validation of the PROMIS Pediatric Sleep Disturbance and Sleep-Related Impairment item banks. Sleep. 2018;41(6):1\u201313. https:\/\/doi.org\/10.1093\/sleep\/zsy054.","journal-title":"Sleep"},{"issue":"6","key":"855_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb16953.x.","journal-title":"Br J Dermatol"},{"key":"855_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.010","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Szepietowski JC, Papp K, Simpson EL, Silverberg JI, Kim BS, et al. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.010.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"855_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/ijms17040462","volume":"17","author":"YS Chang","year":"2016","unstructured":"Chang YS, Chiang BL. Mechanism of sleep disturbance in children with atopic dermatitis and the role of the circadian rhythm and melatonin. Int J Mol Sci. 2016;17(4):462. https:\/\/doi.org\/10.3390\/ijms17040462.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"855_CR28","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.jaip.2021.04.064","volume":"9","author":"AB Fishbein","year":"2021","unstructured":"Fishbein AB, Cheng BT, Tilley CC, Begolka WS, Carle AC, Forrest CB, et al. Sleep disturbance in school-aged children with atopic dermatitis: prevalence and severity in a cross-sectional sample. J Allergy Clin Immunol Pract. 2021;9(8):3120\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.064.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"855_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/children8111057","volume":"8","author":"KA Kelly","year":"2021","unstructured":"Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children (Basel). 2021;8(11):1057. https:\/\/doi.org\/10.3390\/children8111057.","journal-title":"Children (Basel)."},{"key":"855_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/JAA.S317009","volume":"14","author":"L Stingeni","year":"2021","unstructured":"Stingeni L, Belloni Fortina A, Baiardini I, Hansel K, Moretti D, Cipriani F. Atopic dermatitis and patient perspectives: insights of bullying at school and career discrimination at work. J Asthma Allergy. 2021;14:919\u201328. https:\/\/doi.org\/10.2147\/JAA.S317009.","journal-title":"J Asthma Allergy."},{"key":"855_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac058","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Andersen YMF, Skov L, Wu JJ, Agner T, Thomsen SF, et al. The association between atopic dermatitis, cognitive function and school performance in children and young adults. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljac058.","journal-title":"Br J Dermatol"},{"issue":"5","key":"855_CR32","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1111\/jdv.17840","volume":"36","author":"J Manjunath","year":"2022","unstructured":"Manjunath J, Silverberg NB, Silverberg JI. Association of atopic dermatitis with poor school behaviours in US children and adolescents. J Eur Acad Dermatol Venereol. 2022;36(5):e346\u20138. https:\/\/doi.org\/10.1111\/jdv.17840.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"855_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","volume":"22","author":"X Gong","year":"2021","unstructured":"Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555\u201366. https:\/\/doi.org\/10.1007\/s40257-021-00610-x.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"855_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","volume":"23","author":"R Bissonnette","year":"2022","unstructured":"Bissonnette R, Call RS, Raoof T, Zhu Z, Yeleswaram S, Gong X, Lee M. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355\u201364. https:\/\/doi.org\/10.1007\/s40257-022-00690-3.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"855_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.010.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"855_CR36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/pde.14328","volume":"37","author":"LF Eichenfield","year":"2020","unstructured":"Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, et al. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. Pediatr Dermatol. 2020;37(6):1030\u20137. https:\/\/doi.org\/10.1111\/pde.14328.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"855_CR37","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, Nagata T. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014.","journal-title":"J Am Acad Dermatol"},{"key":"855_CR38","unstructured":"Japan Tobacco. JT receives approvals of CORECTIM\u00ae ointment 0.25% and CORECTIM\u00ae ointment 0.5% for the treatment of pediatric atopic dermatitis in Japan. 2021. https:\/\/www.jt.com\/media\/news\/2021\/pdf\/20210323_E1.pdf. Accessed 22 Feb 2023."},{"key":"855_CR39","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM et al. A phase 3 study of ruxolitinib cream in children aged 2\u2013<12 years with atopic dermatitis (TRuE-AD3): 8-week analysis. 32nd European Academy of Dermatology and Venereology (EADV) Congress; 2023 October 11\u201314; Berlin, Germany."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00855-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:18:13Z","timestamp":1719033493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00855-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"10 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Incyte Corporation (Wilmington, DE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LFE has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Amgen, Arcutis, Aslan, Bristol-Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi\u2013Genzyme, Target RWE, and UCB. ELS is an investigator for AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, and Regeneron and is a consultant with honorarium for AbbVie, Eli Lilly, Forte, Galderma, Incyte, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and Valeant. KP has received honoraria or clinical research grants as a consultant, speaker, scientific officer, advisory board member, and\/or steering committee member for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Bausch Health\/Valeant, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite, Celgene, Coherus, Dermira, Dow Pharmaceuticals, Eli Lilly, Galderma, Gilead, GlaxoSmithKline, Incyte, InflaRx, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Merck (MSD), Merck Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Sun Pharmaceuticals, Takeda, and UCB. JCS has served as an advisor for AbbVie, LEO Pharma, Menlo Therapeutics, Novartis, Pierre Fabre, and Trevi; has received speaker honoraria from AbbVie, Eli Lilly, Janssen-Cilag, LEO Pharma, Novartis, Sanofi-Genzyme, and Sun Pharma; and has received clinical trial funding from AbbVie, Almirall, Amgen, Galapagos, Holm, Incyte, InflaRX, Janssen-Cilag, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, Trevi, and UCB. AB has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi; served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi\u2013Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. LK has served as an investigator, consultant, or speaker for AbbVie, Amgen, Anaptys, Arcutis, Dermavant, Eli Lilly, Glenmark, Incyte, Kamedis, LEO Pharma, L\u2019Oreal, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and Taro. JIS received honoraria for advisory board, speaker, and consultant services from AbbVie, Asana, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, LEO Pharma, Menlo, Novartis, Pfizer, Realm, Regeneron, and Sanofi and research grants for investigator services from GlaxoSmithKline and Galderma. ECS has received consulting fees from AbbVie, Boehringer Ingelheim, Incyte, LEO Pharma, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB, and Verrica; has served as a contract researcher for AI Therapeutics; has received grant funding from Pfizer; has served as an investigator for Janssen; has received institutional funding related to clinical trial sponsorship from Janssen, Lilly, Pierre Fabre, Regeneron, and Verrica; and has served as a data safety monitoring board member for LEO Pharma, Novan, Pfizer, and UCB. MEK and MEV were employees of Incyte at the time of the study. HK and HR are employees and shareholders of Incyte. ASP has served as an investigator, speaker, or data safety monitoring board member for AbbVie, Abeona, Aegerion Pharma, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Catawba, Dermavant, Eli Lilly, Galderma, InMed, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi\/Genzyme, Seanergy, TWI Biotechnology, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Incyte Corporation (Wilmington, DE) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase 1 studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (e.g., USA, Europe Union, and Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte\u2019s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at:","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were approved by the relevant institutional review board or ethics committee at each study site.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent\/assent was provided by all patients before enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LFE, MEK, and MEV made substantial contributions to the conception and design of the work. LFE, ELS, KP, JCS, AB, and LK all made substantial contributions to the acquisition of data. HR made substantial contributions to the analysis of the data; all authors made substantial contributions to the interpretation of data. All authors drafted the work and revised it critically for important intellectual content, approved the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}